Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases

Executive Summary

Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases; the firm's Series A follows a record-breaking year for biopharma venture capital. In public company financings, AveXis and others seek cash to fuel R&D.

Advertisement

Related Content

Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard (Part 2)
Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard
Celgene Eyes IO Growth With BeiGene China Pact
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
US IPOs In Review: Relatively Muted Market In 2016 To Continue In 2017
Immuno-Oncology: Sneak Peek Of Preclinical Candidates Waiting In The Wings
Recent Financings Of Private Companies, October 2014
Pherecydes Pharma SA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel